11.05.2012 - Swedish vaccine adjuvant company Isconova AB (Uppsala) has appointed a new CEO. Sven Andréasson took over from Russel Greig, who in turn assumed Ulf Tossman's post as the firm's Chairman of the Board.
Andréasson comes in from Beta-Cell NV (Brussels) and brings in nine years of experience as CEO of Active Biotech AB. Isconova wants to move forward with key clinical studies, strengthen corporate development activities, and enhance revenues from its saponine-based Matrix technology. In 2011, it had vaccine sales of a7.7m, –35.8% less than in 2010.http://www.european-biotechnology-news.com/people/bio-people/2012-2/sven-andreasson.html